Re: First Amendment of Research and License Agreement, Dated April 15, 2004, by and Among BioLineRX Ltd., Ramot at Tel Aviv University, Ltd and Bar-Ilan Research and Development Company Ltd. the "Agreement")
EXHIBIT
10.9
June __,
2004
▇▇▇▇▇▇
▇▇▇▇▇▇
▇.▇. ▇▇▇
▇▇▇▇▇
▇▇▇▇▇▇▇▇▇,
▇▇▇▇▇
▇▇▇▇▇▇
Attn: CEO
Dear
Sirs,
|
|
Re:
|
First Amendment of
Research and License Agreement, Dated April 15, 2004, by and Among
BioLineRX Ltd., Ramot at Tel Aviv University, Ltd and Bar-Ilan Research
and Development Company Ltd. the
"Agreement")
|
You have brought to our attention the
fact that Section 9.1.1 of the Agreement (Licensor Confidential Information) has
created a problem with respect to your ability to enter into agreements with
potential contractors/collaborators and to attract
investors. Specifically, the provision states that your obligations
of confidentiality and non-use (other than for the purposes of the Agreement)
remain in effect during the term of the agreement, and for five (5) years
thereafter. As you have explained to us, potential
contractors/collaborators are unwilling to be bound by such confidentiality and
non-use obligations with respect to the Confidential Information (as defined in
the Agreement) for such undefined term. Therefore, in order to enable
you to continue to develop Licensed Product (as defined in the Agreement) and to
exercise your rights and fulfill your obligations under the Agreement, we hereby
agree to amend the agreement as follows, effective immediately:
The
following shall be inserted at the end of Section 9.1.1:
"Notwithstanding
anything to the contrary in this Section 9.1.1, Bioline may disclose
Licensor Confidential Information to actual and potential business partners,
collaborators, investors, contractors, service providers and consultants,
provided, in each case, that such recipient of Confidential Information first
enters into a legally binding agreement with BioLine which imposes
confidentiality and non-use obligations with respect to Confidential Information
comparable to those set forth in this Agreement for a period of least five (5)
from the date of disclosure of Licensor Confidential Information to such
recipient."
All other
provisions of the Agreement shall remain unchanged.
Please
indicate your agreement to the above amendment to the Agreement by signing
below.
|
Sincerely,
|
||||
|
Ramot
at Tel Aviv University Ltd.
|
Bar-Ilan
Research and Development
|
|||
|
Company
Ltd.
|
||||
|
By:
|
/s/
▇▇▇▇▇ ▇▇▇▇▇▇▇▇
|
By:
|
/s/
▇▇▇▇▇▇▇ ▇▇▇▇▇
|
|
|
Name:
|
▇▇▇▇▇
▇▇▇▇▇▇▇▇
|
Name:
|
▇▇▇▇▇▇▇
▇▇▇▇▇
|
|
|
Title:
|
CEO
|
Title:
|
CEO
|
|
Agreed
to and Accepted:
|
By:
|
/s/ ▇▇▇▇ ▇▇▇▇▇▇▇ /s/ ▇▇▇▇▇▇
▇▇▇▇▇▇
|
|
|
Name:
|
▇▇▇▇
▇▇▇▇▇▇▇ ▇▇▇▇▇▇ ▇▇▇▇▇▇
|
|
|
Title:
|
VP
Finance CEO
|